NHS Patient Achieves Transfusion Independence Following CRISPR Gene Therapy for Beta Thalassaemia
Key Insights
A 36-year-old woman with beta thalassaemia (search) has become transfusion-independent after receiving Casgevy gene therapy at UCLH (search), marking the first successful treatment in southern England.
The CRISPR-based therapy edits patients' stem cells to produce fetal haemoglobin (search), with clinical trials showing 93-98% of patients achieving transfusion independence for at least one year.
The treatment represents a potential cure for transfusion-dependent beta thalassaemia (search), offering hope to patients who previously required blood transfusions every three weeks throughout their lives.
Kavita Mehta spent her first Christmas in 36 years without planning around blood transfusions after becoming one of the first patients in southern England to receive CRISPR gene therapy for beta thalassaemia (search) on the NHS. The groundbreaking treatment at University College London Hospital (search) (UCLH (search)) has enabled her body to produce its own red blood cells for the first time since birth.
Mehta, who has transfusion-dependent beta thalassaemia (search) (TDT), previously required blood transfusions every three weeks due to her body's inability to produce sufficient haemoglobin, the protein responsible for oxygen transport in red blood cells. The condition left her severely tired, weak, and short of breath, while the frequent transfusions caused iron accumulation leading to potential organ damage.
Revolutionary CRISPR-Based Treatment
The therapy, called Casgevy, represents a major advancement in treating beta thalassaemia (search), which primarily affects people of Asian, Mediterranean, and Middle Eastern descent. The treatment uses the patient's own stem cells, which are removed and edited over a six-month period to produce haemoglobin before being reintroduced through infusion.
"I cannot believe that doctors have already seen signs that I am now able to produce my own red blood cells," Mehta said. "I can't tell you what this means to me, and to my family who have had to watch me go through this and care for me."
The CRISPR technique targets DNA to switch on fetal haemoglobin (search) production, overcoming the body's inability to produce sufficient adult haemoglobin (search) that characterizes beta thalassaemia (search). Shortly after birth, fetal haemoglobin is normally replaced by adult haemoglobin, but patients with beta thalassaemia cannot produce enough functional adult haemoglobin.
Clinical Success and Recovery
Mehta received four vials of Casgevy in November during a procedure lasting three and a half hours. Following intensive chemotherapy preparation, she spent six weeks in hospital for monitoring as her body accepted the edited stem cells. She was discharged in mid-December and is now recovering at home.
UCLH (search) haematology consultant Dr. Ben Carpenter, who treated Mehta, reported positive outcomes: "It has been more than two weeks since Kavita's last red cell transfusion, and her levels are continuing to rise independently. We are now seeing normal red blood cells being produced by her own bone marrow for the first time since she was born."
International clinical trials have demonstrated impressive efficacy, with Casgevy eliminating the need for blood transfusions for at least one year in 93-98% of patients. Dr. Carpenter described the success rate as "fantastic," calling the therapy "a game-changer for the transfusion dependent thalassemia community."
Life-Changing Impact
Diagnosed at one month old while living in Kenya, Mehta has endured a lifetime of medical interventions. Her treatment regimen included not only regular transfusions but also nightly iron chelation therapy involving 10-hour overnight infusions five nights per week to prevent iron overload.
"Iron chelation used to be a slow 10-hour overnight infusion, five nights a week. It dictated everything – my weekends, school mornings, even nights out when I got older," Mehta explained. The family's frequent relocations due to her father's work required constant coordination of medical care across ten different countries.
The therapy offers hope for a cure, with patients needing to remain transfusion-independent for one year to be considered cured. Previously, the only effective cure for thalassaemia was stem cell transplantation, which faces challenges including donor shortages and potential complications from immune rejection.
Future Implications
The NHS became one of the first health systems globally to offer Casgevy for beta thalassaemia (search), providing new hope for patients who previously faced lifelong dependence on transfusions and associated complications including diabetes, poor bone health, severe infections, liver damage, and heart failure.
Mehta and her husband have undergone fertility treatment to preserve embryos, as the chemotherapy required before Casgevy affects fertility. While initially advised to wait two years before conceiving, improving blood parameters may allow them to start a family sooner.
"I'd love to travel for longer than four weeks, that would be amazing," Mehta said, looking forward to a life free from the constraints of regular medical appointments. "I've heard some people say that your energy levels just increase tenfold, and you never feel that kind of slump after two to three weeks, which is very exciting for me."